Literature DB >> 14669949

The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation.

Terry J Smith1.   

Abstract

Graves' disease when fully expressed affects the thyroid gland and connective tissues of the orbit and pretibium. While the glandular disease is relatively well-characterized, the pathogenesis of the orbital and dermal components remains enigmatic. In the following article, we review some of the evidence suggesting that fibroblast activation in Graves' disease might play an integral role in the tissue remodeling associated with ophthalmopathy. The thyrotropin receptor (TSHR) is expressed at low levels in several connective tissue depots and by their derivative fibroblasts, including those from the orbit. Little direct evidence currently links extra-thyroidal TSHR expression with Graves' disease. Very recent observations now implicate the insulin-like growth factor-1 receptor (IGF-1R) as a fibroblast activating antigen. When immunoglobulins from patients with the disease, with or without clinical ophthalmopathy, bind IGF-1R on the surface of fibroblasts, the receptor becomes activated and upregulates the expression of two T lymphocyte chemoattractants, IL-16 and RANTES. Thus, IGF-1R may represent a second self-antigen with a pathogenic role in extra-thyroidal Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669949     DOI: 10.1080/08916930310001603000

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  22 in total

Review 1.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 2.  The pathophysiology of thyroid eye disease: implications for immunotherapy.

Authors:  Raymond S Douglas; Shivani Gupta
Journal:  Curr Opin Ophthalmol       Date:  2011-09       Impact factor: 3.761

Review 3.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

Review 4.  Insights into the role of fibroblasts in human autoimmune diseases.

Authors:  T J Smith
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

5.  Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.

Authors:  Seema Kumar; Michael Coenen; Seethalakshmi Iyer; Rebecca S Bahn
Journal:  Thyroid       Date:  2015-08-19       Impact factor: 6.568

6.  B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.

Authors:  Raymond S Douglas; Vibharavi Naik; Catherine J Hwang; Nikoo F Afifiyan; Andrew G Gianoukakis; Daniel Sand; Shweta Kamat; Terry J Smith
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

7.  Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease?

Authors:  Rebecca S Bahn
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-08-26

Review 8.  Immune mechanisms in thyroid eye disease.

Authors:  Geniece M Lehmann; Steven E Feldon; Terry J Smith; Richard P Phipps
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

9.  Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy.

Authors:  Daniel G Ezra; Jonathan Krell; Geoffrey E Rose; Maryse Bailly; Justin Stebbing; Leandro Castellano
Journal:  J Clin Pathol       Date:  2012-05-03       Impact factor: 3.411

10.  Association of IL12B polymorphisms with susceptibility to Graves ophthalmopathy in a Taiwan Chinese population.

Authors:  Yu-Huei Liu; Ching-Chu Chen; Li-Ling Liao; Lei Wan; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  J Biomed Sci       Date:  2012-11-19       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.